Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FA-PEG-BQAV-Re(CO)3+
- Development stage
- Preclinical
- Modality
- Small Molecules, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
FA-PEG-BQAV-Re(CO)3+ appears to be a rationally designed drug conjugate that integrates a folic acid (FA) moiety (for targeting folate receptors highly expressed on some cancer cells), a polyethylene glycol (PEG) linker (to enhance circulation time and stability), a BQAV pharmacophore or scaffold (exact identity unspecified in search results), and a rhenium tricarbonyl core ([Re(CO)3]+), likely used for imaging, as a radiometal tag, or as a biologically active component. The purpose is cancer targeting and potentially theranostics (combined therapeutic and diagnostic utility). The FA enables targeting via folate receptor-mediated endocytosis on tumor cells; PEG improves pharmacokinetics; the Re(CO)3+ metal complex can allow radiolabeling or imaging, or have direct cytotoxic/metallodrug properties. This platform is representative of tumor-targeted, metal-based drug conjugates designed for enhanced selectivity and efficacy in oncology.
- Other names
- FA-PEG-BQAV-Re(CO)3+
02
Targets
FOLR1 (FRα)DNA
Beyond the preview
Go deeper on FA-PEG-BQAV-Re(CO)3+.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FA-PEG-BQAV-Re(CO)3+.